Reduced levels of ITGB1 cause activation of p38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib – novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled Authors: Neha Agrawal, Mythreyi Narasimhan, Rahul Mojidra, Bhausaheb Bagal, Navin Khattry, Anant Gokarn, Sachin Punattar, Rukmini Govekar Published: 2026 ABSTRACT AbstractBackgroundOncogenic tyrosine kinase activity of BCR::ABL1 is causally associated with chronic phase (CP) of chronic myeloid leukemia (CML) and its inhibition by tyrosine kinase inhibitors (TKIs) induces remission in majority of patients. However, in the terminal blast crisis (BC) phase, 80% patients are resistant to TKIs. Forty percent among them are resistant despite inhibition of BCR::ABL1 activity by TKIs and in earlier study, we observed similar antithesis in K562 cells resistant to TKI-imatinib. We demonstrated active BCR::ABL1 signaling downstream of inactivated BCR::ABL1 and its causal association with resistance. This study explores the involvement of ITGB1, integrin with significant role in genesis of CML and differentially expressed in resistant K562 cells, in mediation of atypical activation of BCR::ABL1 pathway and thus resistance.MethodsImatinib-sensitive and resistant K562 cells as well as sensitive cells with ITGB1 knockdown (KD) to mimic resistant cells, were analyzed for proteome and phosphoproteome by mass spectrometry and kinome was profiled by quantification of kinase activities in an array-based assay. The commonality between differentially expressed proteins (DEPs) identified in resistant cells and ITGB1-KD cells together with ITGB1 interactors, identified from ITGB1-immunoprecipitate by mass spectrometry, provided a comprehensive sketch of ITGB1-mediated signaling in resistant cells. The proteins identified as key players in ITGB1-mediated activation of BCR::ABL1 signaling were validated in K562 and KU812 cells, CD34+ cells from patient samples and their functional significance was assessed by inhibition studies in K562 cells.ResultsIt was observed that the reduced levels of ITGB1 in resistant cells activated BCR::ABL1 downstream signaling kinases- p38MAPK and ERK. Though not influenced by ITGB1, LYN was active in resistant cells. Inhibition studies revealed that p38MAPK, ERK and LYN regulate the activity of each other, thereby explaining ITGB1-independent activation of LYN. The three kinases in turn activate members of CDK, MAPK, AKT and PKC families while ERK alone modulates EPH activity.ConclusionThus, reduction in level of ITGB1 in resistant cells leads to activation of ERK and p38MAPK belonging to BCR::ABL1 pathway, despite inactivation of BCR::ABL1, which in turn leads to activation of LYN. Together, these kinases activate members of vital pro-survival pathways, thereby imparting imatinib resistance in CML-BC cells.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12964-026-02893-1.Keywords: Chronic myeloid leukemia, BCR::ABL1, Imatinib resistance, Proteomics, Mass spectrometry Introduction Aberrant cellular signaling is an integral part of oncogenesis and, therefore, has been explored to identify onco-targets [1–3]. A glaring example is a constitutively active tyrosine kinase BCR::ABL1, encoded by a fusion gene resulting from a reciprocal chromosomal translocation t (9;22) (q34; q11) [4], which is causally associated with CML [5]. In the experimental system, signaling downstream of BCR::ABL1 is sufficient to induce the initial CML-CP-like condition [6], which has translated into a successful targeted therapy involving inhibition of the oncogenic activity of BCR::ABL1 by TKI-imatinib mesylate. The inhibitor induces cytogenetic remission in 87% of CP patients [7]. Few fail to respond to the treatment, and others, after initial response, turn unresponsive during the lifelong administration of the non-curative therapy to sustain remission [8, 9]. This has an unfavorable outcome of disease progression to the terminal BC phase, wherein 80% of patients are resistant to most of the TKIs [10] and the survival is 7–11 months [11]. The challenge in managing resistance in the majority of patients in BC is its distinct feature. While in CP, resistance occurs due to non-inhibition of BCR::ABL1 activity by TKIs owing to several mechanisms [12–14], resistance in 40% of BC patients occurs despite inhibition of BCR::ABL1 activity by imatinib [15, 16]. This indicates that BCR::ABL1-independent resistance mechanisms, in addition to those associated with non-inhibition of BCR::ABL1 activity in CP, are operational in BC. The mechanism needs to be explored to identify alternate therapeutic targets for CML-BC, which may provide avenues for combination treatment strategies that target alternative survival signaling, which results in BCR::ABL1-independent resistance [17]. We have earlier reported that despite inhibition of BCR::ABL1 activity by imatinib in resistant K562 cells, BCR::ABL1 downstream signaling components, p38MAPK and 14–3-3ε, are in a state indicative of active pathway [18]. We further showed that experimental reversal of their active state reversed the resistant phenotype [18]. It was therefore pertinent to investigate what caused the BCR::ABL1-independent activation of its downstream signaling molecules. In the same proteomic study [18], ITGB1 (β1 integrin) appeared as a differentially expressed cell membrane protein. Neither our proteomic study nor literature identified ITGB1 as a component of the BCR::ABL1 pathway. However, acknowledging its important role in hemopoiesis [19, 20], genesis of CML [21] and in CML biology [22, 23], its role in atypical activation of BCR::ABL1 signaling in CML-BC was investigated. In the previous proteomic study, as compared to imatinib-sensitive cells, ITGB1 protein levels were found to be low in the imatinib-resistant K562 and KU812 cells. Thus, in this study along with K562 and KU812 cells sensitive and resistant to imatinib, sensitive K562 cells with ITGB1-KD were analyzed. ITGB1 being a signaling receptor and, interplay of kinases and phosphoproteins being the core of cellular signaling, profiles of proteome, kinome and phosphoproteome of these cells were investigated in K562 cells. DEPs common to resistant and KD cells in each ‘omic’ profile served to find common molecular alterations. These could be the events modulated by ITGB1 and associated with imatinib resistance in CML-BC cells. The interactome of ITGB1 was identified which provided useful inputs for the construction of the pathway modulated by ITGB1. The integration of these findings and assessment of their functional significance by inhibition of differentially active kinases, led to the identification of a cascade of modulation of kinase activities initiated by reduced levels of ITGB1. Validation of these observations in imatinib-sensitive and -resistant K562 and KU812 cells and CD34+ cells derived from CML patients, highlighted an important segment of signaling in the BCR::ABL1-independent mechanism of resistance to imatinib in CML-BC. Materials and methods Generation of imatinib-resistant cells The CML-BC cell lines K562 and KU812 were analyzed in this study. The wild type-imatinib-sensitive (K562/S; KU812/S) cells were gifted by Dr. Tadashi Nagai, Jichi Medical University, Tochigi, Japan. They were maintained in RPMI-1640 medium (ThermoFisher Scientific, USA # 23400–021), supplemented with 10% fetal bovine serum (FBS) (ThermoFisher Scientific, USA # 10270–106) and 1% antibiotic–antimycotic (ThermoFisher Scientific, USA # 15240–062), referred to as complete RPMI (cRPMI). Their resistant counterparts (K562/R; KU812/R) were developed by gradual dose escalation of imatinib (Cell Signaling Technology, USA # 9084-S). Starting with 0.1 μM imatinib, the dosage was incremented by 0.1 μM after every three passages to a maximum of 1 μM. The dose was escalated only after the cell viability reached 90% in the previous dose. The entire process of developing resistant cells spanned a period of about 5 months. Half maximal inhibitory concentration (IC50) of imatinib for K562/S, K562/R, KU812/S and KU812/R cells was determined using 3-(4,5-dimethyl-2-thiazolyl)−2,5-diphenyltetrazolium bromide (MTT) assay. K562/R and KU812/R cells were always maintained in a medium containing imatinib at a concentration at which cells could be cultured for long-term without loss of viability and resistance. Determination of IC50 by MTT assay K562/S, K562/R, K562/S cells with ITGB1-KD, KU812/S and KU812/R cells (0.3 × 106) were suspended in 4 ml of cRPMI and 100 µl of the suspension was distributed in each well of a 96-well plate. The plate containing 7500 cells/well was incubated at 37 °C overnight. The cells were treated separately with different concentrations of imatinib, asciminib, dasatinib, nilotinib and ponatinib in triplicate for 48 h at 37 °C. Dimethyl sulfoxide (DMSO) served as a vehicle control. After 48 h of incubation, 30 µl of MTT (HiMedia, India # TC-191) (5 mg/ml) reagent was added per well and incubated for 4–6 h at 37 °C. Thereafter, 100 µl of 0.01 N acidified sodium dodecyl sulphate (SDS) was added to each well and incubated overnight at 37 °C. Colorimetric measurement of the reaction mixture was done at 570 nm in a spectrophotometer (Cytation5: BioTek, USA). IC50 value was calculated from the plot of % cell viability versus concentration of the drug. Patient samples Patients and healthy volunteers were recruited under the project approved by the Ethics Committee of Tata Memorial Centre (TMC). Genomic analysis carried out previously in CML patients and healthy volunteers in the project showed amplification of LYN and p38MAPK genes, only in patients resistant to imatinib [24] which were validated by western blotting as described later to detect the levels of both proteins. The details of patients and processing of samples are described in Supplementary Information. Knockdown of ITGB1 in K562/S cells To generate ITGB-KD cells, two shRNA (TRCN0000275083, SC35674-SH) for ITGB1 in TRC2-pLKO puro vector were used (Sigma-Aldrich Chemical Co., USA # SHC001). K562/S cells (0.2 × 106) were seeded in a 35 mm plate containing 800 µl RPMI and incubated overnight at 37 °C. The transfection mix was prepared by adding transfection reagent (3 µl) Xtreme gene HP (Sigma-Aldrich Chemical Co., USA #06366244001) and plasmid (3 µg) (vector integrated with scrambled shRNA or vector integrated with ITGB1 shRNA) in the ratio of 1:1 to 200 µl RPMI and incubated for 30 min at RT. The transfection mix was added to the cells dropwise and incubated at 37 °C. After 24 h of incubation, an additional 1 ml RPMI was added to the plate. After 72 h, cells were harvested, washed with phosphate buffered saline (PBS), and cultured in cRPMI containing puromycin (1 µg/ml). When the viability of transfected cells reached approximately 95%, 0.1 × 106 cells were suspended in 300 µl cRPMI and subjected to single-cell sorting on FACS Aria lll (Becton, Dickinson and Company, USA). The sorted cells were seeded into 96 well plate containing 150 µl cRPMI with puromycin. Cells were incubated at 37 °C until visible cell clusters were formed and scaled up by growing in 60 mm plates. Monoclonal populations were again subjected to puromycin selection and in the selected population ITGB1 level was quantitated by western blotting. Efficiency of KD was assessed by comparing the level in KD (KD2) to VC and the same were used for omics analyses. Efficiency of KD was further confirmed by comparing a scrambled control (Scr) to two KDs (KD1 and KD2). Scrambled control and KD2 were compared to assess the effect of ITGB1 KD on levels of DEPs identified by omics analyses. In-solution digestion of proteins and phosphoproteins for mass spectrometric analysis ITGB1-KD (KD2) and VC cells were processed for protein profiling and K562/S, K562/R. For phosphoprotein profiling by liquid chromatography-tandem mass spectrometry (LC–MS/MS), ITGB1-KD2 and VC cells were processed as previously described for proteomic profiling of K562/S and K562/R cells [18]. Briefly, cells were harvested, washed with PBS and lysate was prepared using SDS lysis buffer (10% glycerol, 2% SDS, 5% β-mercaptoethanol, and 62.5 mM Tris pH 6.8). For in-solution digestion, proteins were precipitated from cell lysates with acetone, denatured by suspending in 6 M urea and protein concentration was determined by Bradford assay [25]. The denatured proteins were reduced by incubating with 200 mM dithiothreitol (DTT) for 1 h at RT followed by alkylation with 200 mM iodoacetamide (IAA) for 1 h in dark. Urea concentration was adjusted to 0.6 M using 1 mM CaCl2. Protein digestion was carried out by adding proteomic grade trypsin (Sigma-Aldrich Chemical Co., USA # T6567) in the ratio of 1:50 trypsin: protein (w/w) and incubated for 16 h at 37 °C. Peptides were then desalted using Pierce ™ microspin columns (ThermoFisher Scientific USA # 84850), dried in a centrifugal vacuum concentrator and reconstituted with 0.1% formic acid (FA) in water to get a final concentration of 0.5 µg/µl. For proteomic analysis the peptides were subjected directly to LC–MS/MS analysis while for phosphoproteomic analysis peptides were subjected to phosphopeptide enrichment before LC–MS/MS. Phosphoprotein enrichment Phosphopeptide enrichment for K562/S, K562/R, ITGB1-KD (KD2), and its VC was done using affinity chromatography by the method previously demonstrated to yield optimum phosphoproteome coverage [26]. Approximately 300 µg tryptic digested peptides were used for phosphopeptide enrichment using FeNTA (Fe-NTA High–Select Phosphopeptide Enrichment kit, ThermoFisher Scientific, USA # A32992) and TiO2 (TiO2 Phosphopeptide Enrichment kit, ThermoFisher Scientific, USA # A32993) affinity chromatography techniques as per manufacturer’s instructions. Peptides enriched using individual enrichment columns were subjected to LC–MS/MS analysis and the data was pooled. Immunoprecipitation of ITGB1, electrophoretic separation of immunoprecipitate and in-gel digestion For identifying the interacting partners of ITGB1, K562/S cells were incubated with lysis buffer (50 mM Tris–HCl, pH 7.5; 150 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS with protease and phosphatase inhibitor cocktail- 1 mM leupeptin, 2 mM Phenyl methyl sulfonyl fluoride, 10 µg/ml pepstatin, 10 µg/ml aprotinin, 1 mM sodium orthovanadate, 1.5 mM sodium fluoride) at 4 °C for 4 h. After centrifugation at 15,000 × g for 10 min at 4 °C, supernatant was collected and incubated with 5 µg of ITGB1 antibody (Santa Cruz Biotechnology, USA # sc59829) overnight at 4 °C under gentle rotation. Protein A agarose (Merck Millipore, USA #16–125) was then added and incubated for 4 h at 4 °C under gentle rotation. The bound proteins were washed three times with washing buffer (50 mM Tris–HCl, pH 7.5; 500 mM NaCl; 0.1% NP-40; 0.05% sodium deoxycholate) and eluted in SDS lysis buffer by heating at 95 °C for 10 min. Proteins precipitated from lysates using the same protocol with isotype control antibody (Sigma Aldrich Chemical Co., USA # M5284) served as a negative control. Immunoprecipitated proteins were resolved by 10% SDS–polyacrylamide gel electrophoresis (PAGE). After electrophoresis, gels were stained with Coomassie blue solution for 30 min at RT with slow shaking at 50 rpm. The lanes in which the immunoprecipitate was loaded were then excised into 1 × 1 cm pieces which were de-stained, equilibrated in 200 µl of 25 mM ammonium bicarbonate solution in 50% acetonitrile (ACN) with continuous vortexing, washed twice for 5 min each with 500 µl D/W, followed by vortexing with 200 µl of 100% ACN for 5 min. After removing ACN, gel pieces were dried in a centrifugal vacuum concentrator for 10–20 min at 35–40 °C. Reduction was done at 56 °C for 45 min using 200 µl 5 mM DTT in 25 mM ammonium bicarbonate. This was followed by alkylation wherein the gel pieces were incubated with 200 µl of 55 mM IAA in 50 mM ammonium bicarbonate in dark for 30 min at RT. The gel pieces were then vortexed with 200 µl of 25 mM ammonium bicarbonate in 50% ACN for 15 min twice and dehydrated in 200 µl of 100% ACN. The dried gels were rehydrated with sequencing grade trypsin (10 ng/ml in 25 mM ammonium bicarbonate buffer, pH 8.0) and incubated overnight at 37 °C. Peptides were extracted from gel pieces with 200 µl 50% ACN and 5% FA and then dried in a centrifugal vacuum concentrator at 40–45 °C, reconstituted in 0.1% FA and desalted using Pierce ™ microspin columns (ThermoFisher Scientific USA # 84850) to be further used for LC–MS/MS analysis. Mass spectrometry The enriched peptides obtained from- biological replicates each of ITGB1-KD (KD2) and VC; the proteins immunoprecipitated with anti-ITGB1 antibody and its isotype IgG; as well as phosphopeptides enriched from K562/S, K562/R, ITGB1-KD and its VC were subjected to LC–MS/MS on nLC-Q-TOF 5600 + (Sciex, USA). Information-dependent acquisition (IDA), data independent analysis (DIA) by sequential window acquisition of all theoretical fragment-ion (SWATH), data normalization, and quantification were done as previously described [27]. Briefly, each sample was spiked with 1 pmol/µl of digested Escherichia coli β-galactosidase (β-gal) peptides (Sciex, USA # 4333606), before injection in MS, which served as an internal standard. Each sample was subjected to one IDA run followed by three DIA (SWATH) runs. Spectral alignment of SWATH runs of all samples was done in Peak View 2.2 software (Sciex, USA) using proteins with a 1% false detection rate (FDR) to carry out retention time calibration. The filtered results were exported to Marker View software v1.3 (Sciex, USA) to extract the list of proteins with their peak areas to be further normalized by the Loess-R method which was found to be optimal for MS data of biological samples in our earlier study [27]. Data from triplicate runs of each sample was pooled, which is a common practice to circumvent inter-run variation [27] and identification of DEPs between comparison groups was done by Student’s t-test using NormalyzerDE tool. Kinase activity profiling The kinase activity profile of K562/S and/R, ITGB1-KD (KD2) and VC, and K562/R cells treated with LYN, ERK and p38MAPK inhibitors individually was measured using the PamChip®-microarrays (PamGene International BV, The Netherlands). The PamChip® arrays measure kinase activity in cell lysates by measuring the phosphorylation of peptide representations of kinase targets/substrates (referred to as phosphosites) that are immobilized on the microarrays. The active kinases in the sample lysates phosphorylate their target on the array. Generic fluorescent-labeled antibodies that recognize phosphorylated residues are used to visualize the phosphorylation. In two types of arrays, each containing phosphosites for 144 serine-threonine kinases (STK) and 196 protein tyrosine kinases (TK), immobilized on a porous ceramic membrane, cell lysates were pumped through the porous membrane. Fluorescently labeled anti-phospho-antibodies were used to detect the phosphorylated immobilized phosphosites in the array. Images of the arrays were captured at several exposures, and BioNavigator® software (PamGene International BV, The Netherlands) was used to calculate the signal values of each phosphosite. Quality control, visualization, image quantification, statistical analysis, and interpretation were done by BioNavigator® software. Biological triplicates of each lysate were assayed on individual chips. Inhibition studies in resistant cells K562/R cells were treated with 10 µM each of LYN (MedChemExpress, USA # HY-12039), ERK (Cell Signaling Technology, USA # 9903S) and p38 inhibitors (Calbiochem #559389) separately for 24 h. DMSO was used as a vehicle control. The cells were harvested and subjected to kinome analysis as mentioned earlier. Western blot analysis of ITGB1, its interactors, differential phosphoproteins and kinases Western blot analysis was carried out to validate detection of ITGB1 interactors and quantitative differences detected in the levels of phosphoproteins in quantitative LC–MS/MS. Levels of phosphorylated and non-phosphorylated forms of kinases with differential activity in kinome array was also checked with western blot analysis. The whole-cell lysates of K562/S and/R and ITGB1-KD (KD2) and its Scrambled Control as well as KU812/S and/R cells were prepared by boiling 1 × 106 cells in 100 µl of SDS lysis buffer for 10 min, immediately placed on ice for 2 min, and centrifuged at 13,000xg for 15 min. The supernatant was collected and stored at −20 °C until use. Lysate corresponding to 0.2 × 106 cells from each sample was resolved on 10% polyacrylamide gel in mini gel electrophoresis system protean III (Bio-Rad, USA) and transferred onto a polyvinylidene fluoride membrane (Merck Millipore, USA # IPVH00010). The blot was stained with 0.1% fast green (Sigma Aldrich chemical co., USA # F7252) and the colorimetric image was captured in the Chemidoc™ MP imaging system (BioRad, USA) for calculating whole lane intensity as a measure of protein quantity. The blot was de-stained with tris buffered saline containing 0.1% tween (TBST) before immunostaining. The conditions used for immunostaining for each antibody are detailed in Supplementary Table 1. The blot was then developed using ECL Prime® developing reagent (Cytiva, UK # RPN2232) and the chemiluminescence images were captured using the ChemidocTMMP imaging system (Bio-Rad, USA). The band and lane intensities were calculated using Bio-Rad Image Lab 6.0.1 software. The band intensities were normalized with their corresponding whole lane intensity. Analysis of protein interactions STRING analysis (https://string-db.org) was done to understand functional associations between the DEPs [28] with experiments and databases as active interaction sources and medium confidence (0.4) as minimum required interaction score. Pathway analysis In proteome, phosphoproteome and kinome analysis, DEPs identified between comparison groups i.e. S vs R and KD vs VC, were subjected to pathway analysis using the Panther Classification System (pantherdb.org). For each comparison group, the pathways were placed hierarchically based on the number of DEPs and the top ten pathways from both the comparison groups were identified for each omics analysis. DEPs from pathways commonly modulated in both the comparison groups were pooled from all the omics analyses and subjected to STRING analysis along with ITGB1 interactors identified in IP-MS analysis. Statistical analysis GraphPad Prism 5 software was used for statistical analysis. Experiments were done on biological triplicates unless stated otherwise. To compare two groups of data, the student's t-test was performed on mean ± standard error of mean (SEM) and a p-value ≤ 0.05 was considered statistically significant. The levels of ITGB1, phospho-p38MAPK/p38MAPK and phospho-LYN/LYN were subjected to Trend analysis in order to check the relative differences between the comparison groups-CML-CP, CML-CP resistant to TKI and CML-BC resistant to TKI. Results IC50 for imatinib sensitive and resistant cell lines IC50 of imatinib for K562/S and K562/R was 0.55 µM and 5 µM, respectively and that for KU812/S and KU812/R was 0.9 µM and 6 µM, respectively (Supplementary Fig. 1A and B). IC50 of imatinib for K562/R was ninefold higher than K562/S and that of KU812/R was 6.6-fold higher than KU812/S which confirmed their resistant phenotype. Other TKIs showed similar trend wherein the IC50 for resistant cells was around ten fold higher than that of sensitive cells in both the cell lines (Supplementary Fig. 1 C, D, E, F, G, H, I and J). ITGB1 knockdown in K562/S cells K562/R and KU812/R cells showed significant decrease in the level of ITGB1 as compared to that in K562/S (Fig. 1Aa) and KU812/S cells (Supplementary Fig. 2A) respectively. Signal for ITGB1 was less in K562/S cells with shRNA-mediated KD of ITGB1 than that of control, vector control (VC: Fig. 1Ab) and scrambled control (Scr: Fig. 1Ac) thereby indicating efficient knockdown (Fig. 1Ab). MTT assay confirmed imatinib resistance in ITGB1-KD cells, with 4-9 fold increase in IC50 for imatinib in ITGB1-KD compared to its Scr control (Fig. 1Ad). A Western blotting of ITGB1 in a) K562/S, K562/R b) ITGB1-KD and vector control c) ITGB1-KD and Scrambled control (Scr). Band intensities were normalized with their corresponding whole lane intensity. All experiments were carried out in biological triplicate. The graph represents mean ± SEM. Statistical significance was assessed by student’s t-test (p value *p<0.05,**p<0.005, ***p<0.001, ****p<0.0005), d) MTT assay for determination of IC50 of imatinib in ITGB1-KD and control MTT assay confirmed drug resistance in ITGB1-KD cells, with 4-9 fold increase in IC50 for imatinib in ITGB1-KD compared to its control. All experiments were done in biological triplicate. Profile of (B) Proteome, C Phosphoproteome. Ba) and Bc): Volcano plots for K562/S vs K562/R and ITGB1-KD vs VC proteome respectively, detected by LC-MS/MS; Bb) and Bd): Top 10 pathways to which majority of the DEPs of K562/R and ITGB1-KD belonged. Among them, the common pathways are shown as orange bar. Ca) and Cc): Volcano plot for K562/S vs K562/R and ITGB1-KD vs VC phosphoproteome respectively, detected by LC-MS/MS of affinity-chromatography-enriched phosphoproteins; Cb) and Cd): Top 10 pathways to which majority of the DEPs of K562/R and ITGB1-KD belonged. Among them, the common pathways are shown as orange bar. Differential proteomic profile of K562/R and ITGB1-KD cells. Proteomic analysis carried out in our previous study [18] identified 381 DEPs between K562/S and K562/R, of which DEPs in K562/R proteome belonged to 77 pathways when analyzed with panther classification tool (Fig. 1Ba and Bb). While in the present study, 95 proteins were found to be differentially expressed between ITGB1-KD and VC, similarly when analyzed by panther classification tool, DEPs in the proteome of ITGB1-KD belonged to 26 pathways (Fig. 1Bc and Bd, Supplementary Table 2). Integrin signaling pathway, cytoskeletal modulation by rho-GTPases and Wnt-signaling pathways were commonly modulated in both K562/R and ITGB1-KD (Fig. 1Bb and Bd). Differential phosphoproteomic profile of K562/R and ITGB1-KD cells The data obtained from phosphopeptides enriched using FeNTA and TiO2 and identified by MS was pooled for each of the analyzed set. Sixty phosphoproteins were differentially expressed between K562/S and K562/R (Fig. 1Ca) while 186 phosphoproteins were differentially expressed between ITGB1-KD and VC (Fig. 1Cc) (Supplementary Table 3). The DEPs in K562/R phosphoproteome belonged to 25 pathways while those in ITGB1-KD belonged to 52 pathways. Cytoskeletal regulation by rho-GTPase, gonadotropin-releasing hormone receptor and FGF signaling pathways were commonly modulated in both K562/R and ITGB1-KD (Fig. 1Cb and Cd). Differential profile of activity of kinases in K562/R and ITGB1-KD cells Kinome analysis (Supplementary Table 4) revealed that among differentially modulated STKs, 33 showed increased and 10 showed decreased activity in K562/R cells while activity of 21 STKs increased and that of 39 decreased in ITGB1-KD (Fig. 2). Among them four families of kinases namely CDK, MAPK, AKT and PKC showed same trend in both the groups (Fig. 2). Among TKs, activity of 34 kinases increased and that of 32 kinases decreased in K562/R cells as compared to S cells. In ITGB1-KD activity of 13 TKs increased while that of 36 decreased (Fig. 2). Among TKs, TRK family showed similar trend in R and ITGB1-KD. Differential kinome activity profiles of STKs in K562/R and ITGB1-KD; TKs in K562/R and ITGB1-KD generated on kinome arrays. (STKs- serine/threonine kinases, TKs- Tyrosine Kinases) Interactome of ITGB1 Mass spectrometric identification of ITGB1- immunoprecipitated proteins from K562/S cells, after negating those identified in the immunoprecipitate of isotype control antibody, showed 51 proteins as ITGB1 interactors (Supplementary Table 5). STRING analysis of the proteins identified in IP-MS placed Ezrin, ANXA2, GAPDH, PKM and moisin as the closest interactors of ITGB1 (Fig. 3A). These five proteins in turn showed connections with other proteins, 14–3-3 being the common interactor to four of the five closest interactors. Though 14–3-3 ε was identified in MS analysis, data on isoforms in MS requires validation by Western blotting [29]. In our earlier proteomic study, 14–3-3ε was demonstrated to be causally associated with resistance. Its presence as ITGB1 interactor was validated in the western blot analysis of ITGB1 immunoprecipitate (Fig. 3B). A Interactors of ITGB1 identified by IP-MS; B Western blotting analysis of ITGB1-immunoprecipitate confirms 14-3-3ԑ to be a binding partner. C and D STRING analysis. Interactions of DEPs belonging to pathways found to be commonly altered in proteomic/phosphoproteomic/kinome analysis of resistant and ITGB1-KD cells. In STRING, DEPs identified in Blue: Kinome, Black: phosphoproteome, Purple: proteome analysis. In sketch (D) green indicates status in the kinome array; red indicates status in the proteomic analysis. * The gene name for 14-3-3 protein zeta is YWHAZ Integration of the DEPs in proteome, phosphoproteome, kinome common to R and ITGB1-KD cells and interactors of ITGB1 DEPs which belonged to pathways commonly altered in K562/R and ITGB1-KD in each of proteome, phosphoproteome, kinome analysis were pooled (Supplementary Table 6 and 7). Though PKCβ did not appear by these criteria, its differentially expressed status in proteomic (Supplementary Table 2) and kinome analysis (Supplementary Table 4) as well as its known interaction with the key differentially expressed 14–3-3, prompted its inclusion in the integrated analysis. Interaction of these DEPs was assessed by STRING analysis. It revealed connections which could link ITGB1 to 14–3-3 and p38MAPK. It was observed that ITGB1 was connecting to p38MAPK through LYN and ERK whereas to 14–3-3 through FAK and ABL (Fig. 3C and D). Validation of differentially expressed kinases and phosphoproteins The changes in the levels of key DEPs, PKCβ, ERK, phospho-ERK, p38MAPK, phospho-p38MAPK, LYN and phospho-LYN identified in proteome, phosphoproteome and kinome analyses were validated by western blotting. 14–3-3ԑ, which was a significant interactor in the interactome of ITGB1 and demonstrated in our previous study to be casually associated with imatinib resistance in CML-BC, was also analyzed by western blotting. ITGB1-KD in K562/S cells altered the levels of BCR::ABL1 pathway proteins-14–3-3ε and p38MAPK. It resulted in reduced levels of 14–3-3ε (Fig. 4A) and increased phosphorylation of p38MAPK (Fig. 4B) in the KD cells as compared to the control. PKC protein, important functional associate of 14–3-3 [30], showed reduced protein levels of PKCβ1 (K562/R and ITGB1-KD: Fig. 4C; KU812/R: Supplementary Fig. 2B) and PKCβ2 (K562/R and ITGB1-KD: Fig. 4D; KU812/R: Supplementary Fig. 2C) in resistant and KD cells. The level of phospho-LYN/LYN was significantly increased in K562/R and ITGB1-KD cells (Fig. 4E). The level of phospho-ERK was observed to be significantly increased in K562/R (Fig. 4F), KU812/R (Supplementary Fig. 2D) and ITGB1-KD (Fig. 4F) cells as compared to K562/S, KU812/S and control cells, respectively. Validation of key DEPs. Western blotting of K562/S, K562/R, ITGB1-KD and VC for (A) 14-3-3ԑ; B phospho-p38MAPK and p38MAPK; C PKCβ1; D PKCβ2; E phospho-LYN and LYN; F phospho-ERK and ERK. Band intensities were normalized with their corresponding whole lane intensity. All experiments were carried out in biological triplicate. The graph represents mean ± SEM. Statistical significance was assessed by student’s t-test (p value *p<0.05,**p<0.005, ***p<0.001, ****p<0.0005) Inhibition studies Significant alterations in the kinome of K562/R cells were observed upon inhibition of LYN, ERK and p38MAPK kinases individually. (Supplementary Table 8). All the three kinases modulated activity of one another. Inhibition of any one of them led to reduced activity of the other two (Supplementary Table 8). Further, in resistant cells, inhibition of each of the three kinases reduced the activities of MAPK, CDK family members while the activity of PKC and AKT family increased. However, ERK alone modulated the activity of Eph family. This was opposite to that observed in ITGB1-KD cells (Fig. 5). Thus, the changes observed in the kinome of resistant cells appeared to be caused by ITGB1 mediated alterations in the activities of ERK, LYN and p38MAPK. However, in the differential kinome of ITGB1-KD, while p38 and ERK were differentials, LYN was not. Thus, it can be inferred that activity profile of CDK, MAPK, AKT and PKC in resistant cells (Fig. 2), is influenced by increased activities of p38MAPK, ERK and LYN, directly and indirectly mediated by reduced ITGB1 respectively. Heatmap for the activities of differentially active kinases identified as common in kinome analysis of ITGB1-KD and that of resistant cells treated individually with inhibitors of LYN, ERK and p38MAPK. CDKs and MAPKs showed increased activity while AKT, PKCs and EPH family showed reduced activity in ITGB1-KD cells. This reversed when LYN, ERK and p38MAPK were individually inhibited in resistant cells. (Red- active kinase, green- inactive kinase) Validation of molecular players associated with ITGB1 mediated activation of BCR::ABL1 pathway in patient samples Validation of key DEPs detected in the integrated analysis of signaling components was done in CD34+ cells, isolated from patient samples, by western blotting. ITGB1 level was found to be reduced in imatinib-resistant patients as compared to responders (Fig. 6A and B). The levels of phospho-p38/p38MAPK and phospho-LYN/LYN (Fig. 6A and B) showed a trend towards increase in imatinib-resistant patients as compared to the responders. This correlated well with the cell line data, which showed increased levels of both the proteins in resistant cells. Validation of key players by Western blot analysis in CD34+ cells separated from the peripheral blood of two independent sets (A and B) of CML patients sensitive (CP) and resistant to imatinib (CP-R and BC-R), as well as from healthy controls (control/BMT). Trend analysis was done to determine the pattern. (CP-Chronic Phase, BC- Blast Crisis, R- Resistant) Discussion Integrins have multifarious functions in the development of hemopoietic cells. They contribute to the physical attachment of progenitors to the niche as well as mediate their migration from the niche [31]. These diverse actions are achieved through interactions with the extracellular matrix and transmission of this information through signaling hubs [32]. Adhesion through β1-integrin receptors to fibronectin not only anchors hemopoietic progenitors to the stroma but also results in direct adhesion-mediated signaling that inhibits progenitor proliferation. In contrast to normal hematopoiesis, CML is characterized not only by abnormal, premature circulation of primitive progenitors in the blood but also by continuous progenitor proliferation [33–35]. Although CML progenitors express the same integrin receptors as normal progenitors, they fail to adhere to stroma and fibronectin. Various mechanisms have been reported to explain this differential behavior of integrins in normal and CML cells. Structural or functional abnormalities of these receptors were reported as one of the reasons [36]. Yuehua Jiang et al. demonstrated that loss of integrin-mediated inhibition of proliferation, characteristic of CML is caused by the inability of p27Kip to inhibit the activity of cdk2 due to the inability of the latter to translocate to the nucleus [37]. In addition to the genesis of CML, the role of integrins in TKI resistance in CML is also reported. Katherina Rothe et al. [38] showed that integrin-linked kinase (ILK), a key constituent of focal adhesions, is highly expressed in TKI-nonresponsive patient cells. Genetic and pharmacological inhibition of ILK impairs the survival of non-responder patient cells, sensitizing them to TKIs. The association of increased expression of integrin β3 and ILK interaction with β integrins with imatinib resistance through the activation of PI3K/AKT, STAT3, and ERK1/2 signaling pathways has been reported by Rothe K et al. [38]. In our study, we have been able to demonstrate the cascade of molecular changes starting from ITGB1 and resulting finally in imatinib resistance in CML-BC. We observed that though both sensitive and resistant cells expressed the β1 isoform of integrin (ITGB1), the levels were significantly reduced in resistant cells. When reduced levels of ITGB1 observed in imatinib-resistant K562 cells were mimicked by knocking down ITGB1 in sensitive K562 cells, the IC50 for imatinib increased 4–9 fold in these cells thereby confirming the causal role of ITGB1 in imatinib resistance. Further, several differentially modulated pathways identified in proteome, phosphoproteome and kinome analysis of ITGB1-KD cells overlapped with those observed in the resistant cells. They were thus pathways which were downstream of ITGB1 and probably involved in resistance. Novelty of investigation in this study was the global profiling of phosphoproteins and the activity of kinases. In the differentially active kinases, the contribution of serine/threonine kinases was comparable to that of tyrosine kinases. Thus, global profiling of kinases in this study gave an edge over a previous report in CML which focused on tyrosine kinases [39] probably because BCR::ABL1 is a tyrosine kinase. Integration of the differential profiles of proteome, phosphoproteome, kinome in resistant cells, as well as interactors of ITGB1, when subjected to STRING analysis, identified two arms of signaling predominant in resistant cells; one leading to p38MAPK via ERK1/2 and the other to 14–3-3ε via ABL and FAK. This is significant as in our previous study [18], we have demonstrated an active state of p38MAPK and 14–3-3ε, the two components of BCR::ABL1 pathway, in imatinib-resistant K562 cells despite inhibition of BCR::ABL1 activity by imatinib and their causal association with resistance. The role of these kinases in resistance is in keeping with the earlier reports. Activation of ERK1/2 by elevated MOS and TPL2 expression has been shown to be involved in dasatinib resistance, and inhibition of these proteins overcomes dasatinib resistance [40]. In a report by Kumar et al., high levels of ERK1/2 were shown to be related with chemoresistance in CML [41]. In another study, it was proposed that inhibition of MEK/ERK signaling could more efficiently kill BCR::ABL1-independent imatinib-resistant CML cells [42]. Further, it has been reported that deficiency of p38MAPKα greatly enhanced the therapeutic efficacy in growth suppression and cytotoxicity of TKIs [43]. This indicates that probably increased activity of this kinase can lead to TKI resistance. In our study, we could connect the lowered level of ITGB1 to activation of these kinases. Though a report mentions that CML cells that adhere to stroma are protected from apoptotic cell death and thus become chemoresistant [41], it is a widely accepted knowledge that in progressive phases, which co-occur with TKI resistance, CML cells lose their ability to adhere to stroma [19, 44]. Further, in STRING analysis, LYN appeared to be the central molecule for the two arms of signaling initiated by ITGB1. This observation supported the report that LYN kinase functions as a regulator of imatinib sensitivity in CML cells and in patients who fail imatinib therapy but have no detectable BCR::ABL1 kinase mutation; persistently activated LYN kinase is detected [45]. Importantly, in the same study, it is concluded that in imatinib-resistant CML cells and patients, LYN activation is BCR::ABL1 independent and occurs by an unknown mechanism. Observations in our study have unraveled this mechanism. From the combined analysis of proteome, phosphoproteome, kinome data, with contribution from identified interactors of ITGB1, p38MAPK, ERK and LYN were identified as the major players in ITGB1 signaling in resistant cells. Moreover, clarity to their interactions came from the kinome profiles obtained upon inhibition of p38, LYN and ERK individually. It was observed that all three kinases positively regulated the activities of one another. However, upon ITGB1-KD, activities of p38 and ERK increased as in the resistant cells but not of LYN. Thus, increased activity of LYN observed in resistant cells could be attributed to its activation by p38 and/or ERK. Thus, KD of ITGB1 has identified important players in BCR::ABL1-independent mechanism of CML-BC. The consistent phenotypic effects observed with two independent shRNAs targeting ITGB1 have strengthened the findings. Further the increased activities of families of pro-survival kinases CDK, MAPK, AKT observed in ITGB1-KD cells which mimic resistant cells, reversed upon inhibition of p38MAPK, ERK and LYN individually in resistant cells. This proved that in resistant cells reduced levels of ITGB1 led to activation of p38MAPK, ERK and LYN which in turn resulted in activation of pro-survival kinases-which can enhance survival of cells under drug pressure to cause resistance.. Levels of phospho-p38MAPK and phospho-LYN, active forms of the respective kinases, in samples from TKI-resistant patients corroborated with that of imatinib-resistant cell line. Though LYN has been proposed as a therapeutic target in BCR::ABL1 independent resistance in CML [46, 47], our study demonstrates a more direct role of p38MAPK in this mechanism of resistance. Moreover, the possibility of expression of stress-induced p38MAPK in leukemic cells traumatized by drug treatment would be more than in normal cells. This points towards p38MAPK as a better therapeutic target than LYN in CML-BC. As observed in cell lines, reduced level of ITGB1 was observed in resistant patients when compared to the sensitive patients. However, the variation observed in the level of ITGB1 across resistant samples was greater as compared to the two kinases. This is expected as approximately half of the resistant patients in BC are reported to exhibit resistance despite inhibition of BCR::ABL1 [15, 16] who would show the atypical resistance mechanism initiated by reduced ITGB1 levels. In others, BCR::ABL1 pathway is active due to the previously known mechanisms such as mutation or amplification of BCR::ABL1 gene [12–14] and thus should not be affected by level of ITGB1. Active BCR::ABL1 pathway in either cases reflects in similar profiles of kinases (p38 MAPK and Lyn) in BCR::ABL signaling pathway. This observation strongly brings out the potential of reduced level of ITGB1 adjunct to activation state of BCR::ABL1 protein as a marker of existence of atypical mechanism of resistance in CML-BC. These interesting and clinically relevant observations deserve validation in a larger cohort of patients. Conclusion This study aimed to understand the role of ITGB1 in BCR::ABL1-independent mechanisms of resistance to TKIs and identify therapeutic targets for CML-BC. Using a multi-omics approach, the study could dissect the signaling cascade initiated due to reduced levels of ITGB1 in resistant cells. The cascade further emphasized that BCR::ABL1 pathway components are activated due to a reduction in the level of ITGB1 in resistant cells, despite inhibition of BCR::ABL1 activity. This provides substantial evidence for the existence of a BCR::ABL1 independent resistance mechanism in CML-BC, which involves activation of BCR::ABL1 signaling by ITGB1. The observation establishes the central role of p38MAPK in the resistance mechanism in CML-BC and strengthens our earlier claim of p38MAPK as a potential target for combination treatment strategies that target alternative survival signaling, which may contribute towards BCR::ABL1-independent resistance. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3: Supplementary Fig. 1: MTT assay for determination of IC50 of TKIs. MTT assay confirmed drug resistance in K562/S and K562/R; KU812/S and KU812/R cells, with 6–9fold increase in IC50 for TKIs in resistant cells compared to their sensitive counterparts. All experiments were done in biological triplicate. Supplementary Material 4: Supplementary Fig. 2: Validation of key DEPs by western blotting in KU812/S and KU812/R cells. A): ITGB1; B): PKCβ1; C): PKCβ2; D): phospho-ERK and ERK. Band intensities were normalized with their corresponding whole lane intensity. All experiments were carried out in biological triplicate. The graph represents mean ± SEM. Statistical significance was assessed by student’s t-test (p value *p<0.05, **p<0.005, ***p<0.001, ****p<0.0005). Supplementary Material 5: Supplementary Fig. 3: Raw images of western blotting and colorimetric images for analysis. Band intensities were normalized with their corresponding whole lane intensity. Acknowledgements We acknowledge Mass Spectrometry facility, ACTREC. Abbreviations Chronic Myeloid Leukemia Chronic Phase Blast Crisis Tyrosine Kinase Inhibitor Knockdown Vector Control Liquid Chromatography- Tandem Mass Spectrometry Immunoprecipitation Fetal Bovine Serum 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide Half maximal inhibitory concentration Dimethyl sulfoxide Sodium Dodecyl Sulphate Deionized Water Serine-Threonine Kinases Tyrosine Kinases Room Temperature Phosphate Buffer Saline Dithiothreitol Iodoacetamide Formic Acid Acetonitrile Polyacrylamide Gel Electrophoresis Information-Dependent Acquisition Data Independent Analysis Sequential Window Acquisition of All Theoretical fragment-ion Beta Galactosidase False Detection Rate Authors’ contributions NA: Experimental work, data analysis, investigation, conceptualization and initial writing, review and editing of manuscript. MN and RM: Contributed equally, experimental work, review and editing of manuscript. BB: Provided patient samples. NK: Provided patient samples. AG: Provided patient samples. RG: Visualization, supervision, conceptualization, project administration and manuscript review and editing. All authors read and approved the final manuscript. Funding This project was funded from the annual operational expenditure of ACTREC. Data availability The mass spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE [48] partner repository. The data for proteomic profile of ITGB1-KD and VC is deposited with the dataset identifier PXD057116 while that for K562/S and K562/R was already deposited in our earlier study with dataset identifier PXD009686. Data for phosphoproteome of K562/S and K562/R, and that of ITGB1-KD and VC are deposited with the dataset identifier PXD050933 and PXD057032 respectively. Data for interactors of ITGB1 is deposited with the dataset identifier PXD056828. Raw data for western blotting analysis is provided in supplementary Fig. 3. Declarations Ethics approval and consent to participate The study, which identified the key DEPs through genomic analysis of patient samples, validated in this study, was approved by the ethics committee of Tata Memorial Centre, India. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3: Supplementary Fig. 1: MTT assay for determination of IC50 of TKIs. MTT assay confirmed drug resistance in K562/S and K562/R; KU812/S and KU812/R cells, with 6–9fold increase in IC50 for TKIs in resistant cells compared to their sensitive counterparts. All experiments were done in biological triplicate. Supplementary Material 4: Supplementary Fig. 2: Validation of key DEPs by western blotting in KU812/S and KU812/R cells. A): ITGB1; B): PKCβ1; C): PKCβ2; D): phospho-ERK and ERK. Band intensities were normalized with their corresponding whole lane intensity. All experiments were carried out in biological triplicate. The graph represents mean ± SEM. Statistical significance was assessed by student’s t-test (p value *p<0.05, **p<0.005, ***p<0.001, ****p<0.0005). Supplementary Material 5: Supplementary Fig. 3: Raw images of western blotting and colorimetric images for analysis. Band intensities were normalized with their corresponding whole lane intensity. Data Availability Statement The mass spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE [48] partner repository. The data for proteomic profile of ITGB1-KD and VC is deposited with the dataset identifier PXD057116 while that for K562/S and K562/R was already deposited in our earlier study with dataset identifier PXD009686. Data for phosphoproteome of K562/S and K562/R, and that of ITGB1-KD and VC are deposited with the dataset identifier PXD050933 and PXD057032 respectively. Data for interactors of ITGB1 is deposited with the dataset identifier PXD056828. Raw data for western blotting analysis is provided in supplementary Fig. 3.